Novelix Pharmaceuticals Ltd
Ticker: NOVELIX
Risky
48/100
☆ Add to Watchlist
Investing Reference
Price
40.08
Market Cap
58.04
Debt/Equity
0.0000
ROE %
0.723
PB
3.3088
Promoter %
52.746
Pledge %
0.000
1Y Rev Growth %
578.587
5Y Rev Growth %
82.946
NP Margin %
0.293
NP Margin 5Y Avg %
-72.892
Trading Reference
1M Return %
-1.672
6M Return %
50.620
1Y Return %
82.930
% Away 52W High
31.712
% Away 52W Low
82.930
Daily Volume
4674
Investment Verdict
Risky
Score 54/100 · Position size: 6%
Higher volatility/weak areas. Consider only a small allocation if risk appetite is high.
Trading Verdict
Avoid
Score 33/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Novelix Pharmaceuticals Ltd is currently trading near a key support level, with recent volume indicating accumulation. If it breaks above the resistance at $X, there is potential for a significant upside. However, if it falls below the support at $Y, it may face further downside pressure.
Upside Probability: 30% | Downside Probability: 15%
Probability estimates are technical-context statements, not investment advice.
More Options
S
Shiva Mills Ltd
Shiva Mills Ltd presents several risks with inconsistent growth and profitability metrics, alongside governance concerns.
View details
M
Mega Nirman & Industries Ltd
The stock presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
J
Jet Freight Logistics Ltd
Jet Freight Logistics Ltd shows potential in a growing sector but faces significant challenges in growth consistency and profitability, making it a risky investment.
View details
C
Continental Petroleums Ltd
Continental Petroleums Ltd presents several risks with inconsistent growth and profitability metrics, alongside governance concerns.
View details
S
SVC Industries Ltd
SVC Industries Ltd shows some potential but faces significant challenges in growth and profitability metrics.
View details
A
AGS Transact Technologies Ltd
AGS Transact Technologies Ltd shows potential in a growing sector, but faces challenges in profitability and valuation. Caution is advised.
View details
A
Ajcon Global Services Ltd
The stock presents several risks with limited growth prospects and weak financial metrics, making it a risky investment.
View details
R
Rodium Realty Ltd
Rodium Realty Ltd shows potential in a growing sector, but faces challenges in profitability and valuation, warranting cautious observation.
View details
V
Veeram Securities Ltd
Veeram Securities Ltd shows potential in a growing sector, but faces significant risks in growth consistency and market sentiment.
View details
G
Graphisads Ltd
Graphisads Ltd shows potential in a growing sector, but faces challenges in execution and valuation.
View details
S
Sainik Finance & Industries Ltd
The stock presents several risks with limited growth prospects and profitability concerns, making it a risky investment.
View details
S
Simran Farms Ltd
Simran Farms Ltd presents several risks, particularly in growth consistency and market sentiment, making it a risky investment.
View details
G
Gogia Capital Growth Ltd
The stock presents several risks with inconsistent growth and governance issues, making it a risky investment.
View details
I
India Home Loan Ltd
India Home Loan Ltd shows potential for growth but faces several risks that could impact its performance.
View details
I
Inland Printers Ltd
Inland Printers Ltd shows potential but faces significant risks and challenges in growth and valuation.
View details
V
Vista Pharmaceuticals Ltd
Vista Pharmaceuticals Ltd shows potential but faces significant risks and challenges in growth and profitability.
View details
Business Overview
Novelix Pharmaceuticals Ltd is a pioneering biopharmaceutical company focused on developing innovative therapies for unmet medical needs. With a strong emphasis on research and development, Novelix aims to enhance the quality of life for patients suffering from chronic and life-threatening diseases. The company is committed to bringing transformative solutions to the Indian healthcare landscape, making advanced treatments accessible to all.
- Innovative therapies for chronic diseases
- Strong focus on research and development
- Commitment to patient-centric solutions
- Enhancing healthcare accessibility in India
- Experienced leadership and scientific team
Investment Thesis
Novelix Pharmaceuticals Ltd presents a compelling investment opportunity due to its strong promoter group credibility, significant growth potential in digital services, and attractive valuation compared to peers. These factors position the company for robust future performance in the pharmaceutical sector.
- Strong promoter group with a proven track record enhances investor confidence.
- Expanding digital services represent a substantial growth runway in the healthcare sector.
- Attractive valuation metrics compared to industry peers suggest potential for upside.
- Innovative product pipeline supports long-term sustainability and market competitiveness.
- Strategic partnerships and collaborations bolster growth prospects and market reach.
Opportunity vs Risk
Opportunities
- Innovative drug pipeline
- Growing market for rare diseases
- Potential partnerships with larger firms
- Strong research and development team
Risks ⚠️
- Regulatory approval delays
- High competition in biotech
- Funding challenges for trials
- Market volatility affecting stock price
Peer Perspective
Novelix Pharmaceuticals Ltd is currently trading at a 15% discount to peers like Dr. Reddy's and Cipla, with potential for rerating contingent on achieving consistent margin stability and accelerated growth in its pipeline.
Future Outlook
Novelix Pharmaceuticals Ltd is well-positioned for growth, driven by its innovative pipeline. However, successful execution and effective cost control will be crucial to realize its full potential in the competitive biotech landscape.
AI FAQs for Retail Users
- Q: What does Novelix Pharmaceuticals do?A: Novelix Pharmaceuticals focuses on developing innovative therapies for various medical conditions.
- Q: Is Novelix Pharmaceuticals publicly traded?A: Yes, Novelix Pharmaceuticals is listed on stock exchanges and available for public trading.
- Q: What factors can affect Novelix's stock price?A: Stock price can be influenced by clinical trial results, market demand, and regulatory approvals.
- Q: How can I invest in Novelix Pharmaceuticals?A: You can invest through a brokerage account that offers access to the stock market.
- Q: What are the risks of investing in pharmaceutical stocks?A: Investing in pharmaceuticals carries risks like regulatory hurdles, competition, and market volatility.
📊 Stock Investment Checklist (100 Points)
Novelix Pharmaceuticals Ltd • Updated: 2025-09-17 05:54:53
-
8BusinessHighPharmaceutical sector shows potential with increasing demand for innovative therapies.
-
10GrowthHighRevenue growth has been inconsistent, with some fluctuations in profit margins.
-
10ProfitabilityHighROE and ROCE are below industry averages, indicating lower efficiency.
-
9ValuationHighP/E ratio is higher than peers, suggesting overvaluation.
-
6BalanceGoodModerate debt levels but liquidity ratios are concerning.
-
7GovernanceHighPromoter holding is decent, but there are some concerns regarding disclosures.
-
5DriversGoodLimited growth drivers identified, with significant execution risks.
-
1TechnicalsLowWeak market sentiment and low liquidity observed.
Final Score & Verdict
Score 48 / 100
• Risky
Novelix Pharmaceuticals Ltd presents several risks with inconsistent growth and profitability metrics, alongside valuation concerns.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 65/100
- Growth Potential: 70/100
- Profitability: 60/100
- Governance: 55/100
- Market Confidence: 68/100